Notch-Jagged1 signaling and response to bevacizumab therapy in advanced colorectal cancer: A glance to radiomics or back to physiopathology?

Jagged-1 Notch signaling pathway bevacizumab colorectal cancer therapy resistance

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2023
Historique:
received: 27 12 2022
accepted: 10 02 2023
entrez: 17 3 2023
pubmed: 18 3 2023
medline: 18 3 2023
Statut: epublish

Résumé

The Notch intracellular domain (NICD) and its ligands Jagged-1(Jag1), Delta-like ligand (DLL-3) and DLL4 play an important role in neoangiogenesis. Previous studies suggest a correlation between the tissue levels of NICD and response to therapy with bevacizumab in colorectal cancer (CRC). Another marker that may predict outcome in CRC is radiomics of liver metastases. The aim of this study was to investigate the expression of NICD and its ligands and the role of radiomics in the selection of treatment-naive metastatic CRC patients receiving bevacizumab. Immunohistochemistry (IHC) for NICD, Jag1 and E-cadherin was performed on the tissue microarrays (TMAs) of 111 patients with metastatic CRC treated with bevacizumab and chemotherapy. Both the intensity and the percentage of stained cells were evaluated. The absolute number of CD4+ and CD8+ lymphocytes was counted in three different high-power fields and the mean values obtained were used to determine the CD4/CD8 ratio. The positivity of tumor cells to DLL3 and DLL4 was studied. The microvascular density (MVD) was assessed in fifteen cases by counting the microvessels at 20x magnification and expressed as MVD score. Abdominal CT scans were retrieved and imported into a dedicated workstation for radiomic analysis. Manually drawn regions of interest (ROI) allowed the extraction of radiomic features (RFs) from the tumor. A positive association was found between NICD and Jag1 expression (p < 0.001). Median PFS was significantly shorter in patients whose tumors expressed high NICD and Jag1 (6.43 months vs 11.53 months for negative cases; p = 0.001). Those with an MVD score ≥5 (CD31-high, NICD/Jag1 positive) experienced significantly poorer survival. The radiomic model developed to predict short and long-term survival and PFS yielded a ROC-AUC of 0.709; when integrated with clinical and histopathological data, the integrated model improved the predictive score (ROC-AUC of 0.823). These results show that high NICD and Jag1 expression are associated with progressive disease and early disease progression to anti VEGF-based therapy; the preliminary radiomic analyses show that the integration of quantitative information with clinical and histological data display the highest performance in predicting the outcome of CRC patients.

Identifiants

pubmed: 36925919
doi: 10.3389/fonc.2023.1132564
pmc: PMC10011088
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1132564

Informations de copyright

Copyright © 2023 Negri, Bottarelli, Pedrazzi, Maddalo, Leo, Milanese, Sala, Lecchini, Campanini, Bozzetti, Zavani, Di Rienzo, Azzoni, Silini, Sverzellati, Gaiani, de’ Angelis and Gnetti.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Front Neurosci. 2011 Jun 14;5:78
pubmed: 21716644
Per Med. 2022 Jul;19(4):277-286
pubmed: 35708161
Future Oncol. 2015;11(23):3167-74
pubmed: 26552022
iScience. 2022 Apr 27;25(5):104306
pubmed: 35602952
Development. 2011 Sep;138(17):3593-612
pubmed: 21828089
Radiother Oncol. 2019 Jun;135:153-160
pubmed: 31015162
Gut. 2020 Mar;69(3):531-539
pubmed: 31101691
Oncogene. 2008 Sep 1;27(38):5132-7
pubmed: 18758482
Nature. 2006 Dec 21;444(7122):1032-7
pubmed: 17183313
Nat Rev Mol Cell Biol. 2006 Sep;7(9):678-89
pubmed: 16921404
Cancers (Basel). 2021 May 17;13(10):
pubmed: 34067631
Front Mol Biosci. 2021 Jan 07;7:613918
pubmed: 33490106
Clin Colorectal Cancer. 2021 Mar;20(1):52-71
pubmed: 33349519
Nat Rev Cancer. 2008 Aug;8(8):579-91
pubmed: 18596824
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3219-24
pubmed: 17296940
Cancer Cell. 2013 Feb 11;23(2):171-85
pubmed: 23375636
Cancers (Basel). 2021 Feb 26;13(5):
pubmed: 33652647
Nature. 2007 Feb 15;445(7129):781-4
pubmed: 17259972
Am J Pathol. 2008 Sep;173(3):865-78
pubmed: 18688026
Sci Rep. 2019 Dec 30;9(1):20326
pubmed: 31889159
Circulation. 2012 Jan 17;125(2):314-23
pubmed: 22147907
Nature. 2008 Jul 31;454(7204):656-60
pubmed: 18594512
Blood. 2000 Mar 1;95(5):1616-25
pubmed: 10688816
Cancer Res. 2011 Oct 1;71(19):6122-31
pubmed: 21825014
Cancer Sci. 2016 Nov;107(11):1705-1716
pubmed: 27589478
Cell. 2009 Jun 12;137(6):1124-35
pubmed: 19524514
Endocr Rev. 2007 May;28(3):339-63
pubmed: 17409286
Front Oncol. 2020 Oct 14;10:575422
pubmed: 33178604
Clin Transl Med. 2020 Jan;10(1):288-293
pubmed: 32508036
Adipocyte. 2012 Jan 1;1(1):46-57
pubmed: 23700510
J Transl Med. 2019 Oct 7;17(1):337
pubmed: 31590671
Biol Reprod. 2014 Mar 13;90(3):53
pubmed: 24478388
Sci Rep. 2019 Oct 25;9(1):15346
pubmed: 31653909
EPMA J. 2018 Feb 21;9(1):77-102
pubmed: 29515689
Proteomes. 2018 Dec 02;6(4):
pubmed: 30513835
Front Biosci (Landmark Ed). 2009 Jan 01;14(8):3094-110
pubmed: 19273260
Nature. 2007 Feb 15;445(7129):776-80
pubmed: 17259973
Cell. 2000 May 26;101(5):499-510
pubmed: 10850492
Int J Mol Sci. 2022 Jun 02;23(11):
pubmed: 35682918

Auteurs

Francesca Negri (F)

Gastroenterology and Endoscopy Unit, University Hospital of Parma, Parma, Italy.

Lorena Bottarelli (L)

Pathology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.

Giuseppe Pedrazzi (G)

Department of Medicine and Surgery, University of Parma, Parma, Italy.

Michele Maddalo (M)

Medical Physics Department, University Hospital of Parma, Parma, Italy.

Ludovica Leo (L)

Department of Medicine and Surgery, University of Parma, Parma, Italy.

Gianluca Milanese (G)

Radiology, Department of Medicine and Surgery, University of Parma, Parma, Italy.

Roberto Sala (R)

Department of Medicine and Surgery, University of Parma, Parma, Italy.

Michele Lecchini (M)

Radiology, Department of Medicine and Surgery, University of Parma, Parma, Italy.

Nicoletta Campanini (N)

Pathology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.

Cecilia Bozzetti (C)

Oncology Unit, University Hospital of Parma, Parma, Italy.

Andrea Zavani (A)

Department of Medicine and Surgery, University of Parma, Parma, Italy.

Gianluca Di Rienzo (G)

Department of Medicine and Surgery, University of Parma, Parma, Italy.

Cinzia Azzoni (C)

Pathology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.

Enrico Maria Silini (EM)

Pathology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Pathology Unit, University Hospital of Parma, Parma, Italy.

Nicola Sverzellati (N)

Radiology, Department of Medicine and Surgery, University of Parma, Parma, Italy.

Federica Gaiani (F)

Gastroenterology and Endoscopy Unit, University Hospital of Parma, Parma, Italy.
Department of Medicine and Surgery, University of Parma, Parma, Italy.

Gian Luigi De' Angelis (GL)

Gastroenterology and Endoscopy Unit, University Hospital of Parma, Parma, Italy.
Department of Medicine and Surgery, University of Parma, Parma, Italy.

Letizia Gnetti (L)

Pathology Unit, University Hospital of Parma, Parma, Italy.

Classifications MeSH